Piper Sandler on Inspire Medical Systems (INSP): 'Recent Stock Move Presents Buying Opportunity'

Piper Sandler analyst Adam Maeder reiterated an Overweight rating and $260.00 price target on Inspire Medical Systems (NYSE: INSP).

The analyst commented: "Recent Stock Move Presents Buying Opportunity. This week, we had the opportunity to meet with INSP management. Our key takeaways are as follows: (1) Solid Q4 delivered despite some impact from hurricanes; (2) 2025 guidance likely conservative and we see worries over the back-half commentary as overblown; (3) P&L leverage expected to continue in ‘25 driven by GM and SG&A lines; (4) Gen 5 soft launch underway and expected to build going forward—full launch appears targeted for 2H:2025; and (5) The removal of the pressure sensor lead with the gen 5 device should reduce procedure times and drive center throughput, make the procedure easier and help onboard more ENT surgeons, and also lower adverse event rates. Shares of INSP have lagged since Monday, which we believe is primarily related to investor consternation around gen 5 physician reimbursement. We think these concerns are overdone and see the recent sell-off as a buying opportunity. Reiterate OW/$260 PT."

For an analyst ratings summary and ratings history on Inspire Medical Systems click here. For more ratings news on Inspire Medical Systems click here.

Shares of Inspire Medical Systems closed at $173.83 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results